Louisville, KY — Neuronetrix has been selected by AnavexLife Sciences Corp. (OTCQB: AVXL) to support the upcoming Phase 2a clinical trial for ANAVEX 2-73, a symptomatic and potentially disease-modifying treatment for Alzheimer’s disease. Neuronetrix will be utilizing their COGNISION™ System to measure and analyze cognitive biomarkers in study participants. The ANAVEX 2-73 study incorporates an adaptive design, with an enrollment of 32 mild to moderate Alzheimer’s disease patients.
Key performance measures will be collected over 6 months, at up to seven (7) sites in Australia. COGNISION™ is an easy to use, reliable system that provides physiological measures of cognitive processing (“cognitive biomarkers”). These biomarkers are particularly important in pharmaceutical development of pro-cognitive therapeutics by providing sensitive measures of targeted drug effects.
“Due to COGNISION™’s cloud based structure, our systems are specifically designed to be used in multisite clinical trials that require immediate data analysis. We are excited to be a part of this important treatment study,” said Dr. Marco Cecchi, Neuronetrix’s Director of Research and Clinical Affairs. Dr. Christopher U. Missling, President and Chief Executive Officer of Anavex added, “Their expertise, reputation, and experience supporting clinical studies were all factors that influenced our decision to select Neuronetrix and their COGNISION™ Systems.”